Disease · MONDO_0011382

Comparisons in its trials88

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

1 to 20 of 88

Download this page as JSON

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Deferiprone vs Deferasirox: deaths from any cause	0 of 193	0 of 197	390	NCT01825512	Trial comparisons
Deferiprone vs Deferasirox: serious adverse events	13 of 193	14 of 197	390	NCT01825512	Trial comparisons
Morphine Group vs Ketamine Group: The Rate of Hospital Admission	34 of 140	26 of 138	278	NCT03431285	Trial comparisons
Morphine Group vs Ketamine Group: Drug-related Adverse Effects	3 of 140	8 of 138	278	NCT03431285	Trial comparisons
Morphine Group vs Ketamine Group: deaths from any cause	0 of 140	0 of 138	278	NCT03431285	Trial comparisons
Morphine Group vs Ketamine Group: serious adverse events	0 of 140	0 of 138	278	NCT03431285	Trial comparisons
Deferiprone vs Deferasirox: Percentage of Successfully Chelated Patients	69 of 125	80 of 146	271	NCT01825512	Trial comparisons
L-Arginine Hydrochloride vs Placebo: deaths from any cause	0 of 129	0 of 142	271	NCT04839354	Trial comparisons
L-Arginine Hydrochloride vs Placebo: serious adverse events	22 of 129	25 of 142	271	NCT04839354	Trial comparisons
Inclacumab vs Placebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs)	87 of 118	97 of 121	239	NCT04935879	Trial comparisons
Inclacumab vs Placebo: deaths from any cause	3 of 118	2 of 121	239	NCT04935879	Trial comparisons
Inclacumab vs Placebo: serious adverse events	23 of 118	27 of 121	239	NCT04935879	Trial comparisons
Voxelotor vs Placebo: deaths from any cause	8 of 120	2 of 116	236	NCT04218084	Trial comparisons
Voxelotor vs Placebo: serious adverse events	63 of 120	43 of 116	236	NCT04218084	Trial comparisons
L-glutamine vs 100% Maltodextrin: serious adverse events	118 of 151	68 of 78	229	NCT01179217	Trial comparisons
Hydroxyurea vs Placebo: deaths from any cause	2 of 104	1 of 103	207	NCT01976416	Trial comparisons
Hydroxyurea vs Placebo: serious adverse events	6 of 104	6 of 103	207	NCT01976416	Trial comparisons
Magnesium Group vs Placebo Group: serious adverse events	13 of 101	12 of 103	204	NCT01197417	Trial comparisons
ICL670 vs Crossover: serious adverse events	97 of 132	34 of 53	185	NCT01090323	Trial comparisons
Inhaled Nitric Oxide vs Placebo: Number of Participants With Acute Chest Syndrome/Pneumonia Requiring Blood Transfusion	8 of 75	7 of 75	150	NCT00094887	Trial comparisons

diseases-2026-09-18-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0011382/comparisons

API reference For AI assistants

Comparisons in its trials88

Sources 6

Read this list from software.